Cited by 203Nanoparticle-Based Drug DeliveryGlioma Diagnosis and TreatmentNanoplatforms for cancer theranostics

Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine

Zou, Yan, Liu, Yanjie, Yang, Zhipeng, Zhang, Dongya, Lu, Yiqing, Zheng, Meng, Xue, Xue, Geng, Jia +2 more·2018·Advanced Materials

Abstract

Glioblastoma multiforme (GBM) is a fatal central nervous system tumor without effective treatment. Chemotherapeutic agents are mainstays in the treatment of glioblastoma. However, the effectiveness of these is seriously hindered by poor blood–brain‐barrier (BBB) penetrance and tumor targeting, together with short biological half‐life. Improved chemotherapy is thus urgently needed for GBM. Multifunctional nanoparticle delivery systems offer much promise in overcoming current limitations. Accordingly, a multifunctional biomimetic nanomedicine is developed by functionalizing the surface of red blood cell membranes (RBCms) with angiopep‐2 and loading pH‐sensitive nanoparticles (polymer, doxorubicin (Dox), and lexiscan (Lex)) using the functionalized cell membrane to generate the novel nanomedicine, Ang‐RBCm@NM‐(Dox/Lex). The studies toward orthotopic U87MG human glioblastoma tumor‐bearing nude mice show that the Ang‐RBCm@NM‐(Dox/Lex) nanomedicine has much improved blood circulation time, superb BBB penetration, superior tumor accumulation and retention. Moreover, effective suppression of tumor growth and significantly improved medium survival time are also observed after Ang‐RBCm@NM‐(Dox/Lex) treatment. The results show that this biomimetic nanoplatform can serve as a flexible and powerful system for GBM treatment which can be readily adapted for the treatment of other central nervous system (CNS) disorders.

Integrity signals

Registry

Crossref · 10.1002/adma.201803717

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Angiopep-2-modified red blood cell membrane-camouflaged polymer with DOX and lexiscan has low immunogenicity and systemic toxicity and improves blood cycle time and tumor accumulation in U87MG glioblastoma tumor-bearing nude mice.

    “The system with low immunogenicity and systemic toxicity improved blood cycle time and tumor accumulation in U87MG glioblastoma tumor-bearing nude mice.”

The citation lists haven’t been fetched yet

References 55 · Cited by 203

Authors
Zou, Y., Liu, Y., Yang, Z., Zhang, D., Lu, Y., Zheng, M., Xue, X., Geng, J., Chung, R., & Shi, B.
Affiliations
  • Henan University (CN)
  • Nankai University (CN)
  • Sichuan University (CN)
  • Macquarie University (AU)
Corresponding author
  • Zheng, Meng
  • Shi, Bingyang
Venue
Advanced Materials
Publisher
Wiley
Published
2018-10-16
Volume
30
Issue
51
Pages
e1803717-e1803717
ISSN
  • 0935-9648 (ISSN-L)
  • 1521-4095
OpenAlex
W2895971888
Cited by
203
References
55
Citations by year
2026: 4 · 2025: 22 · 2024: 23 · 2023: 31 · 2022: 43 · 2021: 37 · 2020: 28 · 2019: 13 · 2018: 2
FWCI
6.56
Type
journal article
Language
en
Open access
closed
Locations
  • Advanced Materials (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (NSFC 31600809, 51803049, U1604177)
  • National Health and Medical Research Council (APP1111611)
  • China Postdoctoral Science Foundation (2017M620299)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
glioblastoma, biomimetic nanomedicine, Angiopep-2, blood-brain barrier penetration, tumor targeting, pH-responsive nanoparticles, doxorubicin, orthotopic xenograft, brain drug delivery, nanoparticle drug delivery
MeSH terms
Animals, Cell Survival, Cell Transformation, Neoplastic, Doxorubicin, Erythrocytes, Glioblastoma, Humans, Peptides, Biomimetic Materials, Cell Line, Tumor, Nanomedicine, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review